By Dr Conor Kerley, PhD, nutrition researcher. I have lived with multiple sclerosis, an autoimmune disease, for more than half my life.
When you are told you have an autoimmune disease, the second thing you do (after the crying, or the Googling, or both) is ask what you can do about it yourself. Diet comes up. Turmeric comes up. And a lot of what you read is either a miracle claim or a shrug.
This article is neither. It goes through the human trials of curcumin, the active compound in turmeric, in people with autoimmune conditions. Ten conditions have been tested. Some results are striking, some are modest, and some trials found nothing. I'll tell you which is which. None of it replaces your consultant's treatment, and nothing here is a reason to stop it.
Quick answer
- Curcumin calms several of the immune signals that drive autoimmune inflammation, which is why it has been tested in people with ten different autoimmune diseases.
- The best evidence is in inflammatory bowel disease, rheumatoid arthritis and psoriasis. A 2022 review of the trials singled those three out [1].
- Smaller trials in lupus, Hashimoto's, oral lichen planus, Behçet's, Takayasu arteritis and motor neuron disease have reported benefits, but they are single studies, mostly small, and need repeating.
- Ordinary turmeric and standard curcumin capsules are very poorly absorbed. The most convincing results come from nanocurcumin, a form built to be absorbed, usually at 80 mg a day or 80 mg two or three times a day.
- Nothing in these trials replaced standard treatment. Curcumin was taken alongside it.
What an autoimmune disease is
Your immune system is supposed to attack things that aren't you. In an autoimmune disease it attacks something that is: the lining of your gut, the joints, the skin, the thyroid, the insulation around your nerves. There are more than 80 recognised autoimmune conditions [2]. The common ones include rheumatoid arthritis, Crohn's disease and ulcerative colitis, psoriasis, multiple sclerosis, lupus, Hashimoto's thyroiditis, Graves' disease, type 1 diabetes, coeliac disease, ankylosing spondylitis, Sjögren's and vitiligo.
If yours is not named there, it is on the A to Z of autoimmune conditions, which lists all of them by body system and links the ones with human curcumin trials.
They differ enormously in what they do to you. They share one thing: inflammation, driven by an immune system that has lost its sense of proportion. That shared mechanism is why one compound can reasonably be tested across so many conditions, and why a result in one of them is worth knowing about if you have another.
Why curcumin is studied in autoimmunity
Curcumin does two things in laboratory studies that make immunologists sit up.
First, it dials down NF-κB, a master switch inside cells that turns on inflammation genes. Less NF-κB activity means less TNF-α, IL-6 and IL-1β, the messenger molecules that keep autoimmune inflammation going [3].
Second, it nudges the balance between two kinds of T cell. Th17 cells drive autoimmune attack. Regulatory T cells (Tregs) hold it back. In cell studies, curcumin lowers the Th17 side and raises the Treg side, in immune cells taken from lupus patients among others [4]. That is the same balance many modern autoimmune drugs try to shift.
The catch, and it is the reason curcumin has a patchy reputation, is that almost none of it gets into you. Turmeric is about 3% curcumin, and most curcumin you swallow passes straight through. That single fact explains a lot of the disappointing trials. Nanocurcumin, where the particles are made small enough to be absorbed, was developed to get around it, and the more recent and more convincing trials below use it.
The conditions with the strongest evidence
Inflammatory bowel disease (Crohn's and ulcerative colitis)
Eighteen human trials, going back to 2005. Most found benefit. Four used nanocurcumin and all four were positive, including a 12-week placebo-controlled trial in active Crohn's where 40% of people on nanocurcumin reached clinical remission versus 0% on placebo [5]. British and European IBD guidance now mention curcumin as an add-on option. The full story, including the trials that failed, is in our IBD article.
Rheumatoid arthritis
Several randomised trials, from a 2012 pilot onwards, have reported less joint pain and lower inflammation markers with curcumin taken alongside standard treatment. Systematic reviews of the arthritis trials point the same way [6]. See curcumin and rheumatoid arthritis.
Psoriasis
Curcumin was tested in psoriasis in mice first ("humans are not mice", as I keep saying), then in people. The human trials, including nanocurcumin studies, report reduced skin inflammation and lower severity scores [7]. See curcumin and psoriasis.
Multiple sclerosis
This is the one I have. Nanocurcumin has been tested in MS in Iranian trials that measured immune markers: lower inflammatory cytokines, higher regulatory T cell counts, and lower levels of inflammation-linked microRNAs, which are small molecules that control which genes are switched on [8]. Symptom results were mixed and the trials were short. Our MS supplements article covers curcumin alongside vitamin D, CoQ10 and the rest.
Ankylosing spondylitis
A small body of work, covered in our ankylosing spondylitis article.
Other conditions where curcumin has been tested
These are single trials, most of them small. I include them because people with these conditions rarely get any evidence at all, not because one trial settles anything.
Lupus (SLE). A placebo-controlled trial in lupus nephritis (lupus affecting the kidneys) gave 500 mg of turmeric three times a day and found significant falls in protein and blood in the urine and in systolic blood pressure [9]. A more recent trial found 1,000 mg of curcumin a day lowered anti-dsDNA antibodies (a marker of lupus activity) and IL-6 [10]. A third trial compared vitamin D, curcumin with piperine, and the two together: the combination did best on disease activity and inflammatory markers [11]. Not every study is positive: a trial of a different turmeric species (Curcuma xanthorrhiza) added to vitamin D found no effect on disease activity [12]. Full article: read more.
Hashimoto's thyroiditis. Two randomised trials, both recent, added curcumin to an anti-inflammatory diet. In one, 57 people were studied; those on curcumin had lower anti-TPO antibodies (less thyroid autoimmunity), lower TSH, and a small rise in HDL cholesterol. The authors wrote that "curcumin may have possible benefits for thyroid autoimmunity" [13]. In the other, curcumin lowered IL-6, hs-CRP and NF-κB, while the diet-only group saw those markers rise [14]. Two trials, short, one country. Promising, not proven. Full article: read more.
Oral lichen planus. This is the condition with the longest curcumin record, going back to a 2007 placebo-controlled trial. High-dose curcuminoids (6,000 mg a day) reduced symptoms and signs in a 2012 trial [15]. A 2020 trial compared oral nanocurcumin with prednisolone, the usual steroid treatment, and found nanocurcumin worked comparably with comparable results [16]. Two systematic reviews and a 2024 meta-analysis conclude curcumin reduces pain and lesion size, with a 2025 review putting it head to head with corticosteroids [17]. Full article: read more.
Behçet's disease. One randomised, double-blind, placebo-controlled trial of nanocurcumin in 36 people with Behçet's reported improved regulatory T cell numbers and function, which is the immune change you want in this condition [18]. Symptom data were secondary. One trial. Full article: read more.
Takayasu arteritis. A four-week placebo-controlled trial found curcumin improved the Birmingham Vasculitis Activity Score and lowered CRP, ESR and TNF-α. The authors put the effect down to curcumin's anti-TNF action [19]. TNF-blocking drugs are a standard treatment for arteritis, with well-known side effects, which is what makes this result interesting. Four weeks and one trial is not enough to act on alone. Full article: read more.
Motor neuron disease (ALS). Not usually classed as autoimmune, but inflammation is part of it and it was in the original series, so it stays. A 12-month, double-blind, placebo-controlled trial in Iran gave 54 people with ALS either 80 mg of nanocurcumin a day or placebo, alongside their usual treatment. After a year, 1 person in the nanocurcumin group (3.7%) had died or needed mechanical ventilation, against 6 in the placebo group (22.2%), a statistically significant difference in survival. No other outcome differed and there were no serious side effects. The authors call for larger and longer trials [20]. A separate six-month study of alpha lipoic acid with vitamins B1, B2 and B12 in people with ALS reported no decline, and some improvement, in quality of life, fatigue and depression scores [21]. Full article: read more.
What the evidence does not show
I would rather you heard this from me than from your consultant, who will say it anyway.
- Most of these trials are small. Thirty to sixty people is typical.
- Most are short. Four to twelve weeks is typical. Autoimmune diseases run for decades.
- Many of the nanocurcumin trials come from one research community in Iran, using one nanomicelle product. Good trials, but the results have not yet been repeated elsewhere.
- Several measured blood markers rather than how people felt or functioned. Lower IL-6 is encouraging. It is not the same as fewer flares.
- The 2022 review of 31 randomised trials across ten conditions concluded curcumin had "good clinical efficacy" in psoriasis, ulcerative colitis and rheumatoid arthritis, and said the other seven conditions simply didn't have enough research to judge [1]. That is an honest summary of where things stand.
Dose and safety
Standard curcumin trials used 1,000 to 6,000 mg a day. Nanocurcumin trials used 80 mg once, twice or three times a day, because far more of it is absorbed.
In the trials, curcumin was taken alongside steroids, mesalazine, immunomodulators, biologics, riluzole and thyroid hormone, with side effects similar to placebo. Curcumin can interact with blood thinners and some chemotherapy drugs, and may affect how some medicines are metabolised. Tell your consultant or specialist nurse before you start. Bring this article.
Frequently asked questions
Will curcumin replace my medication?
No. In every trial above, curcumin was added to standard treatment, not swapped for it.
Is turmeric in food enough?
No trial has used culinary turmeric. A teaspoon gives under 100 mg of poorly absorbed curcumin.
How long before I'd notice anything?
The trials that saw changes saw them at four to twelve weeks. If nothing has changed after three months, it probably isn't going to.
Why nanocurcumin rather than a high-dose ordinary capsule?
Because absorption, not dose, is the problem. Nanocurcumin gets more into the tissues at a fraction of the dose, and the positive trials cluster around it.
Which autoimmune condition has the best evidence?
Inflammatory bowel disease, then rheumatoid arthritis and psoriasis.
Where Gold Standard Curcumin fits
If you are thinking about it, talk to your team first.
References
Entries marked "from Dr Kerley's files" await his citations; everything else is pinned to the published record.
- Zeng L, Yang T, Yang K, et al. Curcumin and Curcuma longa extract in the treatment of 10 types of autoimmune diseases: a systematic review and meta-analysis of 31 randomized controlled trials. Front Immunol. 2022;13:896476. PMID 35979355.
- Autoimmune conditions: more than 80 recognised. [full citation from Dr Kerley's files]
- Mechanism (NF-κB, TNF-α, IL-6, IL-1β): Palizgir MT, et al. Curcumin reduces the expression of interleukin 1beta and the production of interleukin 6 and tumor necrosis factor alpha by M1 macrophages from patients with Behcet's disease. Immunopharmacol Immunotoxicol. 2018;40(4):297-302. PMID 29806793.
- Handono K, et al. Treatment of low doses curcumin could modulate Th17/Treg balance specifically on CD4+ T cell cultures of systemic lupus erythematosus patients. Cent Eur J Immunol. 2015. PMID 26862311. Also: Curcumin and berberine arrest maturation and activation of dendritic cells derived from lupus erythematosus patients, 2024, PMID 38284733.
- Sugimoto K, et al. Highly bioavailable curcumin derivative ameliorates Crohn's disease symptoms: a randomized, double-blind, multicenter study. J Crohns Colitis. 2020;14(12):1693-1701. PMID 32412598.
- Daily JW, Yang M, Park S. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. J Med Food. 2016;19(8):717-729. And: Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 2012;26(11):1719-1725.
- Psoriasis human trials: see the reference list of our psoriasis article (Kurd 2008; Antiga 2015; Bilia 2018; Kolahdooz 2023).
- Dolati S, et al. Nanocurcumin improves regulatory T-cell frequency and function in patients with multiple sclerosis. J Neuroimmunol. 2019. PMID 30683426. Also Dolati S, et al. 2018: PMIDs 30340096, 29852475, 29194612 (cytokines, Th17, microRNA).
- Khajehdehi P, et al. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J Ren Nutr. 2012;22(1):50-57. PMID 21742514.
- Sedighi S, et al. The effects of curcumin supplementation on inflammatory markers in systemic lupus erythematosus patients: a randomized placebo-controlled trial. Eur J Nutr. 2024. PMID 39546036.
- Randomised clinical trial: the combination of vitamin D and curcumin-piperine attenuates disease activity and pro-inflammatory cytokine levels in systemic lupus erythematosus patients. 2024. PMID 38299416 (Wahono CS, et al. Curr Rheumatol Rev. 2024). [note: the original post gives the piperine dose as "15,800 mg", which cannot be right; likely 15.8 mg. Check the paper]
- Wahono CS, et al. Effect of Curcuma xanthorrhiza supplementation on systemic lupus erythematosus patients with hypovitaminosis D given vitamin D3, on disease activity (SLEDAI), IL-6 and TGF-beta1. Int J Rheumatol. 2017. PMID 29445400.
- Hashimoto's thyroiditis RCT, n=57, anti-inflammatory diet with or without curcumin: anti-TPO, TSH, HDL. [full citation from Dr Kerley's files; the original post dates it 2026]
- Hashimoto's thyroiditis RCT: IL-6, hs-CRP, NF-κB. [full citation from Dr Kerley's files; the original post dates it 2026]
- Chainani-Wu N, Madden E, Lozada-Nur F, Silverman S Jr. High-dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen planus. J Am Acad Dermatol. 2012;66(5):752-760. PMID 21907450. Earlier: Chainani-Wu N, et al. A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. Phytomedicine. 2007;14(7-8):437-446. PMID 17604143.
- Kia SJ, Basirat M, Mortezaie T, Moosavi MS. Comparison of oral nano-curcumin with oral prednisolone on oral lichen planus: a randomized double-blinded clinical trial. BMC Complement Med Ther. 2020;20(1):328. PMID 33129289.
- White CM, Chamberlin K, Eisenberg E. Curcumin, a turmeric extract, for oral lichen planus: a systematic review. Oral Dis. 2019;25(3):720-725. PMID 30614166. Moayeri H, et al. Effects of curcumin on the treatment of oral lichen planus symptoms: a systematic review and meta-analysis. BMC Oral Health. 2024;24(1):104. PMID 38233780. Al-Maweri SA, et al. Curcumin versus corticosteroids for symptomatic oral lichen planus: a systematic review and meta-analysis. Clin Exp Dent Res. 2025;11(5):e70227. PMID 40977174.
- Abbasian S, et al. Nanocurcumin supplementation ameliorates Behcet's disease by modulating regulatory T cells: a randomized, double-blind, placebo-controlled trial. Int Immunopharmacol. 2021;101(Pt B):108237. PMID 34653732.
- Shao N, et al. Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-alpha: a randomized placebo-controlled double-blind clinical trial. Immunol Res. 2017. PMID 28349250.
- Ahmadi M, et al. Safety and efficacy of nanocurcumin as add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a pilot randomized clinical trial. Neurotherapeutics. 2018;15(2):430-438. PMID 29352425. [matches the 54-patient, 12-month, 80 mg trial described in the original post]
- Alpha lipoic acid with vitamins B1, B2 and B12 in ALS, six-month study. [full citation from Dr Kerley's files; was: verify; no citation in the original post]
---
